Last updated: February 20, 2026
What is the Drug with NDC 00168-0203?
NDC 00168-0203 is identified as Exenatide (brand name Byetta), a GLP-1 receptor agonist indicated for type 2 diabetes mellitus. This drug is prescribed to improve glycemic control by enhancing insulin secretion and suppressing glucagon secretion.
Market Overview
Market Size and Growth
The global diabetes treatment market reached a value of $60 billion in 2022. The segment for GLP-1 receptor agonists, including exenatide, is expanding rapidly, driven by increased incidence of type 2 diabetes and evolving treatment guidelines favoring injectable therapies with added cardiovascular benefits.
- Estimated Global Exenatide Market (2022): $5 billion
- Projected CAGR (2023–2028): 8%
Competitive Landscape
Major competitors include:
- Semaglutide (Ozempic, Rybelsus): Dominates the market with higher efficacy and improved dosing.
- Dulaglutide (Trulicity): Prevalent due to weekly dosing.
- Liraglutide (Victoza): Well-established with additional cardiovascular benefits.
Exenatide's market share has declined from 25% in 2018 to approximately 12% in 2022, primarily due to newer formulations with better patient compliance.
Key Market Drivers
- Growing incidence of type 2 diabetes globally.
- Increasing approval of combination therapies.
- Expanding awareness of injectable GLP-1 agents’ cardiovascular benefits.
- Favorable reimbursement policies for diabetes therapies.
Pricing Trends and Projections
Current Pricing Landscape
- List Price (Wholesale Acquisition Cost): Approximately $1,200 per 60-dose pen (2 mg/dose).
- Average Transaction Price (2022): $950 per unit.
- Reimbursement Rate: Varies by region; typical insurance cover reduces patient out-of-pocket to around $25–$50 per dose.
Price Trends (2018–2022)
| Year |
Average Wholesale Price (AWP) |
Key Factors |
| 2018 |
$1,250 |
Market entry of Gila monster peptide; initial premium pricing. |
| 2019 |
$1,200 |
Price stabilization as competition emerges. |
| 2020 |
$1,150 |
Slight discounts due to generic or biosimilar development. |
| 2021 |
$1,200 |
Price stability; increased demand in certain markets. |
| 2022 |
$1,200 |
No significant change; market saturation factors persist. |
Future Price Projections
- Short-term (2023–2025): Prices expected to remain stable or slightly decline (~3–5%) due to increased competition and market pressures.
- Medium-term (2026–2030): Prices projected to decrease by approximately 10–15%, reaching an average of $1,020–$1,100 per unit, driven by biosimilar entry and formulary negotiations.
Regulatory and Patent Landscape
- Patent Expiry: Patent for Byetta expired in 2013, leading to biosimilar development.
- Biosimilar Market Entry: A biosimilar version gained approval in 2021, contributing to downward pricing pressure.
- Regulatory Changes: Recent policies favoring biosimilars reduce market exclusivity, influencing future pricing.
Investment and Commercialization Implications
- Manufacturers focusing on new formulations (e.g., once-weekly exenatide) or combination products may command premium pricing.
- Biosimilar entrants are likely to disrupt current market prices, emphasizing the need for early market entry strategies.
- Price erosion will impact revenue projections, requiring adjustments in long-term planning.
Summary Table: Key Data Points
| Aspect |
Data |
| Current price (2023) |
~$950–$1,200 per 60-dose pen |
| Market share (2022) |
12% of GLP-1 receptor agonist market |
| CAGR (2023–2028) |
8% |
| Biosimilar presence |
Approved in 2021, increasing market competition |
| Price projection (2026–2030) |
$1,020–$1,100 (approximate, 10–15% decrease) |
Key Takeaways
- NDC 00168-0203 (exenatide) is a declining market segment relative to newer GLP-1 therapies.
- Prices currently hover around $950–$1,200; future prices are expected to decline modestly.
- Biosimilar competition significantly influences pricing trends.
- Market growth persists due to rising diabetes prevalence, but margins shrink with increased competition.
FAQs
Q1: Will exenatide regain market share over newer GLP-1s?
A1:** Unlikely, as newer medications offer less frequent dosing and additional benefits, overshadowing exenatide’s position.
Q2: How will biosimilar entry affect pricing?
A2:** Biosimilars typically reduce prices by 15–30%, accelerating market price declines.
Q3: Are there upcoming formulations that could alter the market?
A3:** Yes, once-weekly formulations and fixed-dose combinations are gaining regulatory approval.
Q4: What regions show the highest growth potential?
A4:** Emerging markets with increasing diabetes prevalence, such as India and Southeast Asia, exhibit higher growth rates.
Q5: What are the key risks impacting future pricing?
A5:** Patent expirations, regulatory changes, and the pace of biosimilar adoption pose risks to stable pricing.
References
- Johnson & Johnson. (2022). Exenatide product overview. Retrieved from [Johnson & Johnson official site].
- MarketsandMarkets. (2023). Diabetes treatments market by drug class. Retrieved from [MarketsandMarkets].
- FDA. (2022). Biosimilar approvals. Retrieved from [FDA.gov].
- IQVIA. (2022). Retail pharmacy market data. Retrieved from [IQVIA].
[1] Citation style: APA 7th edition.
